XRTX

POS AM - XORTX Therapeutics Inc. (0001729214) (Filer)

POS AM - XORTX Therapeutics Inc. (0001729214) (Filer)

6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

CALGARY, Alberta, April 21, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce that it has received a letter of compliance from the Nasdaq Stock Market LLC's ("Nasdaq") Listing Qualifications Department in connection with Nasdaq Rule 5550(a)(2) that requires a listed company's shares to maintain a minimum bid price of US$1.00 per share (the "Minimum Bid Requirement"). In order to regain compliance, the Company's common shares were required to trade at or above US$1.00

6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

• VB4-P5 – novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney disease • CALGARY, Alberta, April 13, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the closing of the acquisition of the Vectus kidney anti-fibrotic asset (the "Acquisition"). The Company announced that it entered a binding term sheet on October 17, 2025 to acquire a Renal Anti-Fibrotic Therapeutic Program (the "Program") from Vectus Bios

6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

CALGARY, Alberta, April 01, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, further to its news release of March 26, 2026, the implementation of its share consolidation on the basis of one (1) new common share for every five (5) old common shares (the "Consolidation") has received all required approvals of the TSX Venture Exchange and Nasdaq Stock Exchange and will occur on April 6, 2026. About XORTX Therapeutics Inc. XORTX is a pharmaceutical company with three clinical

6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the results of its annual and special meeting of shareholders (the "Meeting") held Tuesday, March 24, 2026. A total of 2,407,148 common shares of the Company were represented at the Meeting, representing approximately 35% of the total number of common shares of the Company issued and outstanding. All matters presented for approval at the Meeting were duly authorized and approved including

CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, further to its news release of March 25, 2026, the Company has delayed the implementation of its share consolidation on the basis of one (1) new common share for every five (5) old common shares (the "Consolidation") from March 27, 2026 to April 6, 2026, and remains subject to the receipt of all required approvals of the TSX Venture Exchange and Nasdaq Stock Exchange. About XORTX Therapeutics Inc.

6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company's board of directors has approved consolidating (the "Consolidation") its common shares ("Shares") on the basis of one post-consolidation Share for every five pre-consolidation Shares, effective March 27, 2025 (the "Effective Date"). The Company will not undergo a name change in connection with the Consolidation. The Consolidation has been approved by the TSX Venture Exchange (the "TSXV

6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

CALGARY, Alberta, March 24, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce that the shareholders of the Company, via ordinary resolution at the annual and special meeting of the shareholders held on March 24, 2026 (the "Meeting"), have authorized the board of directors of the Company (the "Board") to complete a consolidation of the issued and outstanding common shares in the capital of the Company ("Common Shares") on the basis of up to five (5) pre-consolidation C

20-F - XORTX Therapeutics Inc. (0001729214) (Filer)

CALGARY, Alberta, March 18, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, in connection with its upcoming annual and special meeting of shareholders to be held on March 24, 2026 (the "Meeting"), three new director nominees will be proposed for election in the place of three of the current nominees. At the Meeting, Messrs. George Scorsis, Richard Grieve and Mika Grasso (collectively, the "New Nominees") will be nominated for election to the Company's board of directors (

6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

Your vote is important – Vote well in advance of the proxy voting deadline: March 20, 2026XORTX's board of directors unanimously recommends that Shareholders vote FOR all resolutionsShareholder questions or need voting assistance? Please contact Laurel Hill Advisory Group by email at assistance@laurelhill.com, or by texting "INFO" to, or calling, 1-877-452-7184 (North American toll-free) or 1-416-304-0211 (outside North America). CALGARY, Alberta, March 13, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressiv

6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

CALGARY, Alberta, March 05, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce that it has filed its notice of meeting, management information circular (the "Circular") and related documents (collectively, the "Meeting Materials") with securities regulators in connection with its upcoming Annual and Special Meeting (the "Meeting") of holders of common shares ("Shareholders"). The Meeting Materials have also been mailed to Shareholders and can be accessed online on XOR

6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

6-K - XORTX Therapeutics Inc. (0001729214) (Filer)

EFFECT - XORTX Therapeutics Inc. (0001729214) (Filer)